PHARMACOLOGY ANALYTIC

药理分析

基本信息

批准号：
8858529
负责人：
MICHELLE A RUDEK
金额：
$ 18.27万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-05-01 至 2016-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8858529
关键词：
Age Animals Antineoplastic Agents Archives Area Back Biological Assay Boxing Calibration Cancer Center Support Grant Cell physiology Clinical Clinical Research Clinical Trials Design Comprehensive Cancer Center Computers Consultations Core Facility Coupled Data Data Analyses Data Storage and Retrieval Databases Drug Kinetics Ensure Enzymes Equipment Equipment and supply inventories Faculty Floor Fluorescence Freezing Funding Grant Health Personnel High Pressure Liquid Chromatography Housing Human Human Resources In Vitro Individual Industry Institution Internet Investigation Ions Laboratories Laboratory Technicians Lead Link Location Maintenance Mass Spectrum Analysis Medical Medical History Methods Mission Monitor NCI Center for Cancer Research Names Pathology Patients Peer Review Pharmaceutical Preparations Pharmacodynamics Pharmacogenetics Pharmacology Plasma Cells Positioning Attribute Principal Investigator Procedures Processed Genes Protein Binding Protocols documentation Published Comment Reagent Reporting Research Research Personnel Resource Sharing Retrieval Running Safety Sampling Secure Services Social Security Number Solutions Specialist Specimen Staging Standardization System Temperature Testing Time Tissues Training Validation Visit Water Writing analytical method anticancer research assay development computerized data processing cost data acquisition design detector drug metabolism falls gene therapy good laboratory practice improved instrument instrumentation mass spectrometer meetings member metabolic abnormality assessment method development oncology operation preclinical evaluation preclinical study programs quality assurance queuine research clinical testing square foot trial design

项目摘要

DESCRIPTION OF SHARED RESOURCE Since the founding of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Analytical Pharmacology Core (APC) in 1985, the primary mission of the APC has been to enable the inclusion of critical pharmacological endpoints in the design of clinical trials and preclinical studies, and stimulate new hypotheses and areas of investigation by providing by-cost, state-of-the-art services. The APC provides state-of-the-art equipment and facilities in 1200 square feet of laboratory space on the first floor of the SKCCC Cancer Research Building (CRBI). The location of the APC is adequate to meet the needs of the SKCCC investigators to investigate the pharmacokientics, pharmacodynamics, and pharmacogenetics of anticancer agents. Services include pharmacological trial design, analytical method development and validation, pharmacokinetic and pharmacodynamic data analysis and interpretation, and consultation for design of in vitro drug metabolism, protein binding studies, non-invasive phenotypic probes for drug metabolizing enzymes, and pharmacogenetic studies. The APC houses five UPLC/HPLC instruments with a UV/fluorescence (1), triple stage quadruple mass spectrometer (3), and a QTrap system with ion trap capabilities (1) for more intricate drug metabolism studies. The APC sample analysis has steadily increased since 2005 and is analyzing more than 4,000 samples/year with 20 new methods developed/year, serving over 26 faculty members who are members of eleven CCSG Programs with the majority of the users having peer-reviewed funding. The requested CCSG funding will support personnel who provide consultative services related to assay development, protocol design, and data interpretation, and who ensure that instrumentation is suitably maintained and available for investigators seeking support from the APC Lay: The ability to quantify drugs and their metabolites in cells, plasma, and tissues is an essential need in research aimed at determining how drugs go through the body and the link to the drug's effects both in animals and in humans. The Analytical Pharmacology Core laboratory provides services to design, conduct, and interpret this data. SKCCC Managed Shared Resource Current Grant Year Reporting Period: January 1, 2010 to December 31, 2010.

自1985年建立Sidney Kimmel综合癌症中心（SKCCC）分析药理学核心（APC）以来共享资源的描述，APC的主要任务是使在临床试验和重创研究的设计中促进关键的药理终点，并激发新的假设和调查领域，并通过提供新的假设和调查领域。 APC在SKCCC癌症研究大楼（CRBI）一楼的1200平方英尺实验室空间中提供最先进的设备和设施。 APC的位置足以满足SKCCC研究人员的需求，以调查抗癌剂的药物，药效学和药物遗传学。服务包括药理学试验设计，分析方法开发和验证，药代动力学和药效学数据分析和解释，以及有关体外药物代谢设计，蛋白质结合研究的设计，用于药物代谢酶的非侵入性表型探针以及药物遗传学研究。 APC包含五种UPLC/HPLC仪器，具有紫外线/荧光（1），三阶段四阶段质谱仪（3）和具有离子陷阱功能（1）的QTRAP系统，以进行更多复杂的药物代谢研究。自2005年以来，APC样本分析已稳步增长，并通过20种新方法分析了4,000多个样本，每年开发了20多种新方法，为11位CCSG计划的成员提供了与同行评审资金的大多数用户一起的成员。请求的CCSG资金将支持提供与测定开发，协议设计和数据解释相关的咨询服务的人员，并确保对仪器进行适当维护并适用于寻求APC LAI的研究人员：量化药物及其在细胞，等离子体中的药物及其代谢物的能力，并且在药物和人类链接中的链接中，对药物的影响是必不可少的。分析药理学核心实验室为设计，进行和解释这些数据提供服务。 SKCCC托管共享资源当前赠款年度报告期：2010年1月1日至2010年12月31日。